ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1806

Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Abstract Number: 0697

Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Abstract Number: 1919

Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis
Abstract Number: 0886

Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample
Abstract Number: 1467

Determinants of Cervical Cancer Screening Patterns Among Women with Systemic Lupus Erythematosus
Abstract Number: 0567

Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
Abstract Number: 1179

Determining Faculty vs. Fellow Preferences for ROSCE Milestone Assessments; Is It Time for a Change in Needs Assessment?
Abstract Number: 1352

Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Abstract Number: 0289

Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Abstract Number: 0258

Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis
Abstract Number: 0265

Development and Preliminary Acceptability of JIActiv, a Social Media-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis
Abstract Number: 1419

Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Abstract Number: 0420

Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis
Abstract Number: 1438

Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Abstract Number: 0157

Development of a Deep Learning Algorithm for the Detection of Sacroiliitis on MRI in Patients with Active Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].